New agents for the treatment of genetically high-risk chronic lymphocytic leukemia

Leuk Lymphoma. 2010 Jan;51(1):3-4. doi: 10.3109/10428190903499702.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chromosome Deletion
  • Cyclophosphamide / administration & dosage
  • Drug Therapy / methods
  • Humans
  • Lenalidomide
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Medical Oncology / methods
  • Risk
  • Rituximab
  • Thalidomide / analogs & derivatives
  • Thalidomide / pharmacology
  • Treatment Outcome
  • Vidarabine / analogs & derivatives
  • Vidarabine / pharmacology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Thalidomide
  • Cyclophosphamide
  • Lenalidomide
  • Vidarabine
  • fludarabine